PubMed Health⌕ Search

Biomedical subjects

A Zaccaria

Publications and source records attributed to A Zaccaria.

At least 109 records · Page 6Linked to original sources
PubMed1986

High-dose therapy followed by autologous bone marrow transplantation (ABMT) in previously untreated non-Hodgkin's lymphoma.

13 previously untreated patients with poor prognosis non-Hodgkin's lymphoma (NHL) underwent high-dose therapy followed by autologous bone marrow transplantation (ABMT). All patients experienced a great cytoreductive effect and 9 of them reached a complete remission (mean duration 32 months). The best results were observed in patients with more limited disease and in those without symptoms. 7 patients still remain in complete unmantained remission 15-46 months from the transplant. The probability of survival is 74% at 46 months. No therapy-related deaths were recorded. In differentiating our preliminary approach, we propose high dose therapy followed by ABMT as induction phase in patients with stage II and as consolidation after first line therapy in patients with stages III-IV. Further studies are warranted to determine which type of lymphoma may benefit more and which conditioning regimens may improve the remission rate.

Adolescent↗
PubMed1985

Chromosome 12 rearrangement with breakage at the p11 level in hematologic disorders: report of four cases.

Four patients with chromosome #12 rearrangement at the p11 level are described. One had acute promyelocytic leukemia, one had myelofibrosis evoluting to acute undifferentiated leukemia, one had acute nonlymphoid leukemia (ANLL) secondary to Hodgkin's disease, and another had acute leukemia recurring after allogeneic bone marrow transplantation. This chromosome abnormality was always associated with other karyotypic aberrations, probably as a secondary event. Possible correlations with recent findings in oncogene research are discussed.

Adult↗
PubMed1985

Muconaldehyde formation from 14C-benzene in a hydroxyl radical generating system.

It has recently been proposed that muconaldehyde, a six carbon, alpha, beta-unsaturated dialdehyde, may be a hematotoxic metabolite of benzene. The present studies indicate that trans, trans-muconaldehyde is formed from benzene in vitro in a hydroxyl radical (.OH) generating system containing ascorbate, ferrous sulfate and EDTA in phosphate buffer, pH 6.7. Muconaldehyde formed from benzene in the .OH generating system was identified by trapping it with thiobarbituric acid (TBA), which results in the formation of an adduct with a 495 nm absorption maximum and a 510 nm fluorescence emission maximum. These maxima were identical to those observed after reacting authentic trans, trans-muconaldehyde with TBA. This finding was supported by thin layer chromatography and solid phase extraction studies. In those studies benzene-derived muconaldehyde cochromatographed with the muconaldehyde/TBA standard. Analyses of the products from the .OH generating system using high performance liquid chromatography (HPLC) confirm that trans, trans-muconaldehyde is a product of benzene ring fission. Regardless of whether or not TBA was used for trapping, samples from the .OH system incubated with benzene contained a peak which cochromatographed with the muconaldehyde standard. The radioactivity profile of fractions collected during HPLC analysis demonstrates 14C-benzene to be the source of the trans, trans-muconaldehyde. The role of hydroxyl radicals in the formation of muconaldehyde was investigated by using dimethyl sulfoxide, mannitol, and ethanol as .OH scavengers. These scavengers, at concentrations of 10 and 100 mM, were found to cause a dose-dependent decrease in the formation of muconaldehyde.(ABSTRACT TRUNCATED AT 250 WORDS)

Aldehydes↗
PubMed1984

Hairy-cell leukemia complicating coeliac disease: report of a case and discussion of possible pathogenetic mechanisms.

10-28% of the patients with chronic coeliac disease develop a second malignancy, such as non-Hodgkin's lymphomas, particularly of the histiocytic type, and adenocarcinomas. The second tumor may arise in the intestinal tract or in other organs. We describe here a patient who developed a tartrate-resistant, acid phosphatase-positive, hairy-cell leukemia after a history of chronic coeliac disease. In the literature, no similar case has been described as yet.

Celiac Disease↗
PubMed1984

Case report of 11q- in M2-acute nonlymphocytic leukemia.

A deletion of chromosome 11, del(11) (q22) was observed in a patient with M2-ANLL, both at diagnosis and at relapse which occurred 3 months after allogeneic bone marrow transplantation. Few similar cases have been reported previously.

Acute Disease↗
PubMed1984

Hodgkin's disease and subacute cerebellar degeneration. A case report and review of the literature.

Case history of a 20-year old man with Hodgkin's disease, clinical stage I, lymphocytic predominance, complicated by a subacute cerebellar degeneration, which was diagnosed by computed tomography scan. Following local radiotherapy, cerebellar and brain stem symptoms and signs had a complete regression. Two months later, a recurrence of the neurological picture was recorded: polychemotherapy (MOPP) was then administered and after 5 courses the symptoms improved considerably. The association of subacute cerebellar degeneration with Hodgkin's disease is rare: only 10 cases have previously been described. Pathogenesis of cerebellar atrophy complicating tumors is undetermined.

Adult↗
PubMed1983

Low dose arabinosyl cytosine for treatment of myelodysplastic syndromes and subacute myeloid leukemia.

Several agents, including arabinosyl cytosine (ARA-C) at a low concentration, can induce leukemic myeloblasts to mature to a variable extent. The therapeutic implications of this observation are worth investigating. A few case-reports have shown that low dose ARA-C can be useful for treatment of the myelodysplastic syndromes (MDS) and of acute myeloid leukemia (AML). However, no information is available yet on the proportion of patients who can be expected to respond. We treated by low dose ARA-C (20-30 mg/sqm/day i.v. or i.m. for 7-10 days) 20 consecutive patients. A complete remission of 5 months was obtained in one of nine cases of subacute myeloid leukemia (SAML). A partial remission (complete normalization of blood counts with a slight excess of marrow blast cells) was obtained twice in one of 11 cases of MDS. An increase of Hb level (more than 11.5 g/dl) was obtained and maintained for 12 months in a case of MDS. A short-lasting increase of granulocyte count was obtained in another two cases of MDS and SAML respectively. It is suggested that low dose ARA-C can advantageously modify the proliferation to maturation imbalance of leukemic cells by slowing down cell proliferation rate. However, the proportion of patients who respond is probably low. This treatment is at a very early experimental stage and should be probably limited to selected cases of MDS and subacute or acute myeloid leukemia.

Adult↗
PubMed1983

Acute nonlymphocytic leukemias and dysmyelopoietic syndromes in patients treated for Hodgkin's lymphoma.

The clinical, hematological, and cytogenetical features of six patients with hematological disorders secondary to Hodgkin's lymphoma (HL), are described. Three patients developed a dysmyelopoietic syndrome (DMS); three, an acute nonlymphocytic leukemia (ANLL). Chromosomal analyses showed a normal karyotype in one case and an abnormal one in five cases: one with a 53-chromosome clone, two with a pseudodiploid pattern plus hyperdiploid subclones, and two with a hypodiploid pattern. Trisomy 21 was observed in two cases, tetrasomy 21 in one case, monosomy 5 and monosomy 7 in two cases. The correlations of chromosomal changes with hematological abnormalities or clinical aspects are discussed.

Acute Disease↗
PubMed1982

Vindesine effect in myeloid leukemia.

Vindesine (VDS), a semisynthetic vinca alkaloid derivative, was given weekly at a dose of 3 mg/m2 as single-agent chemotherapy to seven patients with chronic myeloid leukemia (CML), 17 patients with chronic myeloid leukemia in blastic metamorphosis (CML/BM), and 12 patients with acute nonlymphocytic leukemia (ANLL). A substantial and rapid decrease of leukemic cells was obtained in 31 of 36 patients, and this was independent of cell phenotype and morphology. VDS may improve the results of polychemotherapy of ANLL, and is useful for palliative treatment of CML/BM.

Antineoplastic Agents↗
PubMed1978

The relevance of extramedullary hemopoiesis to the staging of chronic myeloid leukemia.

In chronic myeloid leukemia (CML) the spleen and the liver can lodge, trap and release a high proportion of leukemic cells, and are active sites of (leukemic) hemopoiesis throughout the disease. Evidence is provided that spleen and liver volume have a prognostic value, and that marrow, spleen, and liver differ as to cell composition, cell kinetic patterns, functional cell characters, and cell karyotype. In the majority of the patients, extramedullary hemopoiesis seems to be more abnormal than marrow hemopoiesis, supporting the hypothesis that spleen and/or liver can play an important role in the evolution of CML towards the blastic metamorphosis. However, present information on extramedullary hemopoiesis does not allow to identify specific patterns and to establish its relevance to the course of the disease.

Bone Marrow↗